New Research Shows How Insulin Reacts With CellsA little more than a century ago, diabetes was looked at as a fatal long-term illness. Today however, thanks to the discovery of insulin, it is looked at more as a chronic disease and due to many medical discoveries in medicine; there are many ways to make diabetes less of a struggle.
A team, which included researchers from Case Western Reserve University School of Medicine released information about their study and what they had discovered, which could lead to remarkable developments in patients who are trying to manage diabetes.
FDA Reviewing Canagliflozin/Invokana For Type 2 Diabetes
An advisory panel of the Food and Drug Administration has recommended the approval of the use of canagliflozin, a new drug that is being developed by Johnson and Johnson, for the treatment of Type 2 diabetes. This new medication — which will be called Invokana if it is eventually approved — is unique in that it lowers blood sugar levels by causing it to be excreted in the urine. As well, patients might also experience weight loss when taking canagliflozin.
According to a study performed by Morris J. Birnbaum, MD, PhD, the Willard and Rhoda Ware professor of Medicine, with the Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania and a team of researchers, the diabetes drug metformin works much differently than what researchers once understood it to work.
Studies performed on mice found that metformin represses the liver hormone glucagon’s capacity to produce a central signaling molecule.
America’s society is dealing with the huge issue of obesity. Many people either don’t have time or do not feel like cooking at the end of the day and with hamburgers and fries so readily available, who really needs to?
Obesity is a growing problem due to overeating and it can develop from high insulin levels as well. Many researchers have suggested it the other way around, that obesity causes high insulin levels. This new theory is based on the testing of mice. It is very much the whole chicken or the egg problem, which one came first?
New Study: Non-Adherence Causing Some Diabetes Cases
Prescribed medication is popular all over the world but a major health concern in the United States is a problem referred to as “non-adherence”. This simply means that people are not taking the medication correctly that has been prescribed to them. When this happens, health issues like diabetes and chronic diseases become more of an issue.
A study that was led by researchers at the University of California, San Francisco, San Francisco General Hospital and Trauma Center and the Kaiser Permanente Division of Research has found a reason as to why medical non-adherence has become such an issue. The cause is ineffective communication.
New study indicates that this is the first time mitoNEET has been altered to expand fat tissue that allowed the study models (mice) to remain metabolically healthy which can help type 2 diabetics in the future.
Research results were released that make a clearer understanding of the metabolic functions of obesity and its connection to Type 2 diabetes. Research studies are ongoing in regards to using this data about the protein mitoNEET in hopes of creating different medications for the treatment of diabetes.
The protein “mitoNEET” is a major part of the cell’s mitochondrion, which is the cell’s energy powerhouse. MitoNEET binds pioglitzaone (Actos TM) an insulin-sensitizing drug that is used in the treatment of Type 2 diabetes.
After two years, the risk of developing diabetes among the breast cancer survivors compared to the women without breast cancer began to increase two years after diagnosis.
New Study On Post-Menopausal Cancer Survivors & Diabetes
Study results indicate that women who have survived breast cancer are more apt to develop diabetes after menopause than women who did not suffer from a bout of breast cancer. These study results were published in the Diabetologia, The Journal of European Association for the Study of Diabetes (EASD). The study was headed by Dr. Lorraine Lipscombe, Women’s College Hospital, Women’s College Research Institute, Toronto, Ontario, Canada.
There have been many published reports where results show a connection between diabetes and cancer, cancer of any form. In particular, though, there is an estimated 20 percent higher risk of diabetes for women after menopause in those who survived breast cancer.
A study by the Mayo Clinic has shown that the diabetic insulin-sensitizing drug Metformin has shown improvement in patients who are suffering from ovarian cancer.
While diabetes is a common fatal disease in the United States, ovarian cancer is quickly growing to be another one to look out for as well. Now there may be a chance to help cure one with one simple pill.
A study by the Mayo Clinic has shown that the diabetic insulin-sensitizing drug Metformin has shown improvement in patients who are suffering from ovarian cancer. Patients with both diabetes and ovarian cancer and took the drug had a better survival rate than those who did not. The drug also helped to slow the growth of and prevent tumors.
The study results indicated that the AIC desired levels were lower than 7.0 during that testing period for the participants in the study. The results were presented at the 9th Annual International Diabetes Federation Western Pacific Region Congress in Kyoto, Japan.
New Study Results Released on Victoza
The maker of the injectable insulin Victoza (aka/ liraglutide), Danish company Novo Nordisk, presented test results at the 9th Annual International Diabetes Federation Western Pacific Region Congress in Kyoto, Japan, on November 27, 2012, that reflected that Victoza is more likely to enable Type 2 diabetics to achieve lower AIC levels during a 26-week period (testing at 12 weeks, 20 weeks and 26 weeks) than does oral Sitagliptin (Januvia) and injectable Exenatide in people with Type 2 diabetes. The study results indicated that the AIC desired levels were lower than 7.0 during that testing period for the participants in the study.
Funded by the Alzheimer’s Association, with a grant of $97,000.00 for research, Dr. Reed will attempt to find the answer to “why” having diabetes increases the odds of developing Alzheimer’s disease.
New Grant Issued To Find Out Why Diabetes Accelerates Alzheimer’s
Past studies have shown that if you have diabetes, you are more likely to be diagnosed with Alzheimer’s disease when you get older, and having diabetes even accelerates the Alzheimer’s progression.
Why? The complete answer is unknown at this time, although many theories have been culled from many different studies.